Ion Channels in Drug Discovery XXII Virtual Meeting

Home/Virtual Conference/Ion Channels in Drug Discovery XXII Virtual Meeting
Loading Events
This event has passed.

Metrion is co-organising and attending the ‘Drug Discovery for Ion Channels XXII’ Virtual satellite meeting. This is a collaborative meeting, organised alongside partners Nanion, Sophion, Fluxion and SB Drug Discovery.

The final line-up of Speakers is given below and can also be found here. The event will start at 8AM PST / 4PM GMT/ 5PM CET.

Please click here to register for the event.

About the meeting:

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. Because of this, ion channels remain an underrepresented target class for drug discovery. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput.

The advent of higher throughput automated electrophysiology systems has begun to change the face of ion channel drug discovery.

Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques.

This year’s meeting will highlight presentations from users of automated electrophysiology instrumentation as well as other speakers in the field of ion channel drug discovery, including several academic speakers.

Speaker line up and timings of the event:

5PM CET – 5:05PM CET – Welcome greeting
5:05PM CET – 5:35PM CET – Networking part one
5:35PM CET – 6:10PM CET – Keynote talk (30 + 5 min)
Dr. Stephen Griffin, Associate Professor, Leeds Institute of Medical Research, School of Medicine, University of Leeds
“Plugging the holes in antiviral therapy – Drug discovery potential of viroporins”
6:10PM CET – 6:35PM CET – Presentation 1 (20 + 5 min)
Dr. David Baez-Nieto, Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT
“Biophysical analyses of rare CACNA1I missense variants reveal a molecular phenotype associated with schizophrenia”
6:35PM CET – 7:00PM CET – Presentation 2 (20 + 5 min)
Professor John Atack, Director, Medicines Discovery Institute, Cardiff University
“GABAA Receptor Modulators – The Story Continues”
7:00PM CET – 7:15PM CET – Networking part two (15 min)
7:15PM CET – 7:40PM CET – Presentation 3 (20 + 5 min)
Dr. Julie Klint, Head of Ion Channel section, Molecular Screening; Lundbeck
“Drug discovery of Kv7.2/7.3 openers – Validation of automated patch clamp multi-parameter readout assay”
7:40PM CET – 8:05PM CET – Presentation 4 (20 + 5 min)
Professor Irina Vetter – Institute for Molecular Bioscience & School of Pharmacy, The University of Queensland
“Neurotoxic venom peptides from the giant Australian stinging tree”
8:05PM CET – 8:30PM CET – Presentation 5 (20 + 5 min) Dr. Andrew Jenkins, Ph.D – Director of Graduate Studies, Molecular & Systems Pharmacology Training Program Associate Professor, Departments of Anesthesiology, Pharmacology & Chemical Biology – Emory University School of Medicine
“GABA(A) receptors and disease”
8:30PM CET – 9:00PM CET – Networking part three
9:00PM CET – 9:05PM CET – Thank you and goodbye

Please email any questions to info@metrionbiosciences.com

Go to Top